TrialBMC urology2010

Type 1 plasminogen activator inhibitor (PAI-1) in clear cell renal cell carcinoma (CCRCC) and its impact on angiogenesis, progression and patient survival after radical nephrectomy.

Dragomir P Zubac et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.